Single-dose etoposide in advanced pancreatic and biliary cancer, a phase II study.

  • Authors:
    • K Ekstrom
    • K Hoffman
    • T Linne
    • B Eriksson
    • B Glimelius
  • View Affiliations

  • Published online on: July 1, 1998     https://doi.org/10.3892/or.5.4.931
  • Pages: 931-935
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Palliative chemotherapy can add to the duration and quality of life in patients with advanced pancreatic and biliary cancer, albeit in a limited way. Between March 1995 and October 1997, 31 symptomatic patients were treated with etoposide in a phase II trial. Measurements of objective and subjective responses were performed, the latter by the treating physician and with the method of clinical benefit response (CBR). Quality of life was evaluated with the EORTC QLQ-C30 questionnaire. A partial response was seen in 2 (6%) patients. Subjective responses/quality of life gains were seen in 6 (19%), 7 (23%) and 9 (29%) patients, respectively, with the different methods. Median survival was 4.5 months. WHO grade 3 and 4 toxicity, alopecia excluded, was seen in 20% of the patients. The clinical activity of etoposide is limited, and in the same low range as other drugs in these diseases.

Related Articles

Journal Cover

Jul-Aug 1998
Volume 5 Issue 4

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ekstrom K, Hoffman K, Linne T, Eriksson B and Glimelius B: Single-dose etoposide in advanced pancreatic and biliary cancer, a phase II study.. Oncol Rep 5: 931-935, 1998.
APA
Ekstrom, K., Hoffman, K., Linne, T., Eriksson, B., & Glimelius, B. (1998). Single-dose etoposide in advanced pancreatic and biliary cancer, a phase II study.. Oncology Reports, 5, 931-935. https://doi.org/10.3892/or.5.4.931
MLA
Ekstrom, K., Hoffman, K., Linne, T., Eriksson, B., Glimelius, B."Single-dose etoposide in advanced pancreatic and biliary cancer, a phase II study.". Oncology Reports 5.4 (1998): 931-935.
Chicago
Ekstrom, K., Hoffman, K., Linne, T., Eriksson, B., Glimelius, B."Single-dose etoposide in advanced pancreatic and biliary cancer, a phase II study.". Oncology Reports 5, no. 4 (1998): 931-935. https://doi.org/10.3892/or.5.4.931